4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial-Reference-Cited by-同舟云学术

4 Weeks Versus 5 Weeks of Hypofractionated High-dose Radiation Therapy as Primary Therapy for Prostate Cancer: Interim Safety Analysis of a Randomized Phase 3 Trial

Published:2018-03 Issue:4 Volume:100 Page:866-870
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Fonteyne Valérie,Sarrazyn Camille,Swimberghe Martijn,De Meerleer Gert,Rammant Elke,Vanderstraeten Barbara,Vanpachtenbeke Frank,Lumen Nicolaas,Decaestecker Karel,Colman Roos,Villeirs Geert,Ost Piet

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference11 articles.

1. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-Year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial;Dearnaley;Lancet Oncol,2016

2. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer;Catton;J Clin Oncol,2017

3. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer;Lee;J Clin Oncol,2016

4. Moderate hypofractionation in high-risk, organ confined prostate cancer: Final results of a phase III randomized trial;Arcangeli;J Clin Oncol,2017

5. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer;Diaz;Int J Radiat Oncol Biol Phys,2004

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating a hypofractionated radiotherapy schedule for prostate cancer at an institution in South Africa;South African Journal of Oncology;2024-07-30

2. Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial;Radiotherapy and Oncology;2024-04

3. Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE Trial;European Urology Oncology;2024-04

4. Microbiome and metabolome dynamics during radiotherapy for prostate cancer;Radiotherapy and Oncology;2023-12

5. Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy;Journal of Applied Clinical Medical Physics;2023-05-11